We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Epigenetic Approach on Colorectal Cancer Systemic Therapy: Promising yet a Long Way to Go.
- Authors
Ayu Rezkitha, Yudith Annisa; Aji Savitri, Camilia Metadea; Lusida, Maria Inge; Yudho Bintoro, Siprianus Ugroseno; Rahmawati, Lita Diah; I'tishom, Reny; Miftahussurur, Muhammad
- Abstract
Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths worldwide. Various genetic and epigenetic changes in colonic epithelial cells, including DNA methylation, histone modifications, and noncoding RNAs, were involved in the initiation and progression of CRC. Moreover, epigenetic changes played an important role in CRC drug resistance. The dynamic and reversibility of epigenetic changes provide new possible therapeutic targets for colorectal cancer. Recent studies have reached the field of development of drugs targeting DNA methyltransferase and histone deacetylases, followed by bromodomain and extra terminal inhibitors alongside RNA-based therapeutics as an emerging cancer therapy. Through this review, we discussed epigenetic changes in CRC alongside potential agents targeting epigenetics and the possibility of implementing these drugs in the clinical setting. As epigenetic regulation is dynamic and dependent, its process warrants further investigation. It is visible that future research needs a combination of completing the ongoing studies, initiating new clinical trials, and developing new agents capable of treating CRC. A combination of expertise needs to be formed to overcome the obstacle in several inhibitors and RNA-based therapeutics to bring forth novel epigenetic agents that are both effective and safe.
- Subjects
COLORECTAL cancer; RNA methylation; SYSTEMIC family therapy; DNA methylation; NON-coding RNA; DISEASE progression; DRUG development; EPIGENOMICS
- Publication
Gaceta Médica de Caracas, 2022, Vol 130, Issue 2, p357
- ISSN
0367-4762
- Publication type
Article
- DOI
10.47307/GMC.2022.130.2.14